RBR-823rst招募中未知
Evaluation of applicability, safety and outcomes motor and cognitive of video game Nitendo Wii Fit Plus® in frail elderly
Faculdade de Medicina da Universidade de São Paulo0 个研究点开始时间: 2016年7月11日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 60Y 至 100Y（—）
入选标准
- •Frail elderly and pre frail will be selected with 60 or older, diagnosed with frailty syndrome according to the criteria of Fried. The elderly should not present neurological or orthopedic diseases that promote the inability to remain in bipedalism and wade; with normal or corrected visual acuity measured by Snellen chart; Good hearing is clinically assessed by the whisper of the test; who did not have previous experience with the Nintendo Wii Fit® and who accept sign the Informed Consent and Informed of the study.
排除标准
- •The elderly will be excluded that during the study period, submit any clinical change that makes it impossible to perform physical exercises in standing position, as cardiorespiratory, orthopedic or neurological disorders; elderly unable to interact with the game; and in the second phase of the study will exclude elderly who are missing for more than three consecutive sessions without replacement.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of efficacy, acceptability and safety of two different solutions of PEG for colonoscopy in children: a prospective randomized trial. - Different PEG solutions for colonoscopy in childreEUCTR2008-003244-11-ITISTITUTO PER L`INFANZIA BURLO GAROFOLO
尚未招募
不适用
Evaluation of the acceptability, safety and effectiveness of thermal ablation in the prevention of cervical neoplasia in ZimbabweCancerPACTR202103552074172International Agency for Research on Cancer184
已完成
不适用
To evaluate the efficacy, safety and tolerability of Hilterapia® (High Intensity Laser Therapy) in the chronic articular inflammatory processes in haemophilic adult patientsHaemophiliaHaematological DisordersISRCTN02847428Baxter (Italy)11
进行中（未招募）
1 期
Evaluation of the therapeutic potential of a low-dose therapy with the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus.Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies.MedDRA version: 18.0Level: PTClassification code 10042945Term: Systemic lupus erythematosusSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersMedDRA version: 18.0Level: PTClassification code 10067657Term: Systemic lupus erythematosus disease activity index increasedSystem Organ Class: 10022891 - InvestigationsEUCTR2013-001599-40-DECharité - Universitätsmedizin Berlin12
已完成
1 期
Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic autoimmune disease (PRO-IMMUN)M32.1Systemic lupus erythematosus with organ or system involvementDRKS00004858Charité - Universitätsmedizin Berlin10